Search | Clinical Trials Finder

Conditions: Hemophilia A
Interventions: rFVIIIFc; Biological
Lead sponsor: Bioverativ, a Sanofi company; Industry
Eligibility: Up to 5 Years · Male only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 20
States / cities: Little Rock, Arkansas • Duarte, California • Sacramento, California + 16 more

Conditions: Acquired Hemophilia A
Interventions: OBIZUR; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 16
States / cities: Aurora, Colorado • Gainesville, Florida • Atlanta, Georgia + 13 more

Conditions: Hemophilia A, Hemophilia B
Interventions: Counseling, Control; Behavioral
Lead sponsor: New York Presbyterian Hospital; Other
Eligibility: 12 Years to 20 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Hemophilia A
Interventions: ReFacto AF; Biological
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 8
States / cities: La Jolla, California • Detroit, Michigan • Chapel Hill, North Carolina + 4 more

Conditions: Hemophilia
Interventions: Coagulation Factor VIIa (Recombinant); Biological
Lead sponsor: Laboratoire français de Fractionnement et de Biotechnologies; Industry
Eligibility: 6 Months to 75 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hemophilia A, Factor VIII (FVIII)
Interventions: Half-life factor VIII based replacement therapy, Non-FVIII based replacement therapy; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 6 Months and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Significant Bleeding Risk
Interventions: Octaplex, Beriplex P/N (Kcentra); Drug
Lead sponsor: Octapharma; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 22
States / cities: Aurora, Colorado • New Haven, Connecticut • Miami, Florida + 14 more

Conditions: Hemophilia A
Interventions: Factor VIII; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 5 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 2
States / cities: Peoria, Illinois • Portland, Oregon

Conditions: Hemophilia B
Interventions: REGV131, LNP1265; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 2 Years and older · Male only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2047
U.S. locations: 14
States / cities: Los Angeles, California • Sacramento, California • San Francisco, California + 9 more

Conditions: Hemophilia A
Interventions: Colorado Adult Joint Assessment Evaluation; Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 4
States / cities: Orange, California • Aurora, Colorado • Indianapolis, Indiana + 1 more

Conditions: Hemophilia, Menstrual Flow Excessive
Interventions: Recombinant FVIII Fc fusion product Eloctate, Recombinant FIX Fc fusion product Alprolix, Patient-operated diagnostic device for anemia AnemoCheck.; Drug · Device
Lead sponsor: Emory University; Other
Eligibility: 14 Years to 55 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hemophilia B, Allergic Reactions
Interventions: Not listed
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: Not listed
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 15
States / cities: Phoenix, Arizona • Orange, California • Atlanta, Georgia + 12 more

Conditions: Hemophilia B, Hemophilia A
Interventions: Standard of Care FIX Replacement therapy, Standard of Care FVIII Replacement therapy; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 13
States / cities: Palo Alto, California • San Francisco, California • Stanford, California + 7 more

Conditions: Hemophilia A
Interventions: Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human coagulation factor VIII; Biological
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2033
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Hemophilia A
Interventions: Kogenate (BAY 14-2222); Drug
Lead sponsor: Bayer; Industry
Eligibility: 12 Years to 60 Years · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 2
States / cities: Detroit, Michigan • Las Vegas, Nevada

Conditions: Hemophilia B
Interventions: PF-06838435/ fidanacogene elaparvovec; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2031
U.S. locations: 17
States / cities: San Francisco, California • Aurora, Colorado • Indianapolis, Indiana + 3 more

Conditions: Hemophilia A
Interventions: OBI-1; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 6 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hemophilia, Hemophilia A
Interventions: Not listed
Lead sponsor: Boston VA Research Institute, Inc.; Other
Eligibility: Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hemophilia B
Interventions: Not listed
Lead sponsor: Spark Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Hemophilia B
Interventions: SB-FIX; Biological
Lead sponsor: Sangamo Therapeutics; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Hemophilia, Hemophilia A, Hemophilia B, Hemophilia A With Inhibitor, Hemophilia B With Inhibitor, Haemophilia B Without Inhibitor, Haemophilia A Without Inhibitor, Haemophilia
Interventions: Not listed
Lead sponsor: American Thrombosis and Hemostasis Network; Network
Eligibility: 0 Years to 13 Years
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 27
States / cities: Phoenix, Arizona • Madera, California • San Diego, California + 24 more

Conditions: Hemophilia A
Interventions: rVIII-SingleChain, Octocog alfa; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 9
States / cities: Sacramento, California • San Diego, California • Aurora, Colorado + 6 more

Conditions: Hemophilia A
Interventions: AAV2/8-HLP-FVIII-V3; Biological
Lead sponsor: University College, London; Other
Eligibility: 18 Years and older · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 3
States / cities: Boise, Idaho • Lexington, Kentucky • Memphis, Tennessee

Conditions: Hemophilia, Sickle Cell Disease, Neoplasms, Blood Coagulation Disorders
Interventions: Medication Education for Children; Behavioral
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 7 Years to 11 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Kansas City, Missouri

Search by objective public record fields.

An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A

Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A

The Effect of Patient Counseling on Adolescent Hemophilia Patient Compliance With Bleeding Logs

Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery

LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures

TG-INSIGHT With Joint POCUS, Hemostatic Potential in Patients With Severe Hemophilia A on Novel Replacement and Substitution FVIII Therapies

Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.

GAS-Hem Feasibility Study

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

Colorado Adult Joint Assessment Scale (CAJAS) Validation

Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers

Study to Describe the Allergic Reactions to Factor IX in Patients With Hemophilia B

A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)

Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A

Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A

A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B

Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A

Improved Factor VIII Inhibitor Evaluation

LTFU for Gene Transfer Subjects With Hemophilia B

Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B

ATHN 8: Previously Untreated Patients (PUPs) Matter Study

An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A

Gene Therapy for Haemophilia A.

Kid Cards: Teaching Kids About Medicines